Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1806 results
June 2018
-
Media ReleaseNovartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis26 abstracts on Cosentyx® (secukinumab) in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) will be presented at the Annual European Congress of Rheumatology (EULAR 2018)[1]…
-
Open resources at Novartis help drive innovation
With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.
-
Media ReleaseNovartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETsPatients reported prolonged maintenance of global health status[1](overall health) Longer time to deterioration (TTD) seen across multiple clinically relevant symptom categories including…
-
Media ReleaseNovartis Schullabor empfängt hunderttausendsten BesucherBasel, 6. Juni, 2018 - Mit dem heutigen Besuch einer Schulklasse des Gymnasiums am Münsterplatz in Basel hat das Novartis Schullabor die magische Zahl von über 100'000 Besucherinnen und Besuchern…
-
Media ReleaseThird Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancerKisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line…
-
Media ReleaseNew Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapyENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna® Findings further support durability and…
-
Key ReleaseNovartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billionBasel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)…
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar adalimumabSandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion…
-
Key ReleaseNovartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraineIf approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package…
May 2018
-
Media ReleaseFDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (…
-
Immuno-oncology researchers seek to build smart drug combos
Novartis has launched a comprehensive research program to help find the right combinations of therapies for the right patients.
-
Media ReleaseNovartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)[1]…
Pagination
- ‹ Previous page
- 1
- …
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- …
- 151
- › Next page